Verona Pharma PLC VRNA
We take great care to ensure that the data presented and summarized in this overview for Verona Pharma plc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding VRNA
View all-
Pentwater Capital Management LP Naples, FL5.3MShares$567 Million3.55% of portfolio
-
Hbk Investments L P Dallas, TX4.26MShares$456 Million6.29% of portfolio
-
Fil LTD Hamilton, D03.49MShares$373 Million0.32% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.38MShares$362 Million15.27% of portfolio
-
Davidson Kempner Capital Management LP New York, NY3.27MShares$350 Million10.89% of portfolio
-
Glazer Capital, LLC New York, NY3.21MShares$343 Million11.48% of portfolio
-
Abingworth LLP London, X02.46MShares$263 Million21.3% of portfolio
-
Nea Management Company, LLC Timonium, MD2.25MShares$241 Million15.02% of portfolio
-
Goldman Sachs Group Inc New York, NY1.94MShares$207 Million0.03% of portfolio
-
Balyasny Asset Management LLC Chicago, IL1.86MShares$199 Million0.27% of portfolio
Latest Institutional Activity in VRNA
Top Purchases
Top Sells
About VRNA
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
Insider Transactions at VRNA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 07
2025
|
Andrew Fisher General Counsel |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,349,887
-100.0%
|
-
|
|
Oct 07
2025
|
Andrew Fisher General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
931,984
+50.0%
|
-
|
|
Oct 07
2025
|
Anders Ullman Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
430,856
-100.0%
|
-
|
|
Oct 07
2025
|
Anders Ullman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
72,000
+50.0%
|
-
|
|
Oct 07
2025
|
Michael Austwick Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
84,712
-100.0%
|
-
|
|
Oct 07
2025
|
Michael Austwick Director |
BUY
Exercise of conversion of derivative security
|
Direct |
72,000
+50.0%
|
-
|
|
Oct 07
2025
|
Mark W Hahn Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
14,550,248
-100.0%
|
-
|
|
Oct 07
2025
|
Mark W Hahn Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,285,280
+50.0%
|
-
|
|
Oct 07
2025
|
Kathleen A. Rickard Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,564,852
-100.0%
|
-
|
|
Oct 07
2025
|
Kathleen A. Rickard Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,131,984
+50.0%
|
-
|
|
Oct 07
2025
|
David Zaccardelli President and CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
15,461,424
-100.0%
|
-
|
|
Oct 07
2025
|
David Zaccardelli President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,285,280
+50.0%
|
-
|
|
Oct 07
2025
|
Lisa Deschamps Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
156,856
-100.0%
|
-
|
|
Oct 07
2025
|
Lisa Deschamps Director |
BUY
Exercise of conversion of derivative security
|
Direct |
72,000
+50.0%
|
-
|
|
Oct 07
2025
|
Vikas Sinha Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
166,112
-100.0%
|
-
|
|
Oct 07
2025
|
Vikas Sinha Director |
BUY
Exercise of conversion of derivative security
|
Direct |
72,000
+50.0%
|
-
|
|
Oct 07
2025
|
Mahendra Shah Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
165,472
-100.0%
|
-
|
|
Oct 07
2025
|
Mahendra Shah Director |
BUY
Exercise of conversion of derivative security
|
Direct |
72,000
+50.0%
|
-
|
|
Oct 07
2025
|
Christina Ackermann Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
136,072
-100.0%
|
-
|
|
Oct 07
2025
|
Christina Ackermann Director |
BUY
Exercise of conversion of derivative security
|
Direct |
72,000
+50.0%
|
-
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 12.9M shares |
|---|---|
| Grant, award, or other acquisition | 450K shares |
| Bona fide gift | 1 shares |
| Sale (or disposition) back to the issuer | 38.1M shares |
|---|---|
| Open market or private sale | 6.13M shares |
| Payment of exercise price or tax liability | 625K shares |
| Bona fide gift | 2.65M shares |